Abstract | PURPOSE OF REVIEW: RECENT FINDINGS:
Monoclonal antibody against IgE has demonstrated its efficacy in reducing the symptoms of asthma and rhinitis. In difficult-to-treat asthma patients it allows a reduction in the dose of inhaled steroids, the number of exacerbations, emergency visits and hospitalizations. Its broad implementation is limited by its high cost because adverse events are not a concern. Specific sublingual immunotherapy gave promising results in clinical trials, while modifying immunoglobulins and cytokine profiles, also inducing T-cell tolerance. Safety issues of subcutaneous immunotherapy have been surpassed by the sublingual route, with equivalent efficacy. The new inhaled steroid ciclesonide is effective in established inflammation, is activated only in the respiratory system, and has negligible systemic effects. SUMMARY:
|
Authors | Carlos E Baena-Cagnani, Giovanni Passalacqua, Maximiliano Gómez, Mario E Zernotti, G Walter Canonica |
Journal | Current opinion in allergy and clinical immunology
(Curr Opin Allergy Clin Immunol)
Vol. 7
Issue 2
Pg. 201-6
(Apr 2007)
ISSN: 1528-4050 [Print] United States |
PMID | 17351477
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal
(immunology, therapeutic use)
- Asthma
(immunology, therapy)
- Child
- Child, Preschool
- Humans
- Immunotherapy
- Middle Aged
- Rhinitis, Allergic, Perennial
(immunology, therapy)
|